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Background: Hepatocellular carcinoma (HCC) is a multi-factor, multi-step, multi-gene and complicated process
resulting from the accumulation of sequential genetic and epigenetic alterations. An important change among
them is from precancerous lesions to HCC. However, only few studies have been reported about the sequential
genetic changes during hepatocarcinogenesis.
Methods: We observed firstly molecular karyotypes of 10 matched HCC using Affymetrix single-nucleotide
polymorphism (SNP) 6.0 arrays, and found chromosomal fragments with high incidence (more than 70 %)
of loss of heterozygosity (LOH). Then, we selected 28 microsatellite markers at some gene spanning these
chromosomal fragments, and examined the frequency of LOH of 128 matched HCC and 43 matched precancerous
lesions-dysplastic nodules (DN) by a PCR-based analysis. Finally, we investigated the expression of proteins encoded by
these genes in HCC, DN and the surrounding hepatic tissues.
Results: The result of Affymetrix SNP6.0 arrays demonstrated that more than 70 % (7/10) cases had chromosomal
fragment deletion on 4q13.3-35.1, 8p23.2-21.2, 16q11.2-24.3, and 17p13.3-12. Among 28 microsatellite markers
selected, LOH frequencies at D8S262 for DN and HCC were found to be the highest, 51.2 % and 72.7 %,
respectively. Immunohistochemically, the positive rate of its adjacent gene CSMD1 in HCC, DN, and the
surrounding hepatic tissues were 27.3 % (35/128), 75 % (33/44), and 82 % (105/128), respectively.
Conclusions: LOH at D8S262 may be associated with an early genetic event of hepatocarcinogenesis, and a predictor
for the monitor and prevention of HCC.
Virtual Slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1557074981159099.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer and the third most common cause of cancer-
related deaths worldwide [1]. Up to 80 % of HCCs develop
against a background of liver cirrhosis related to hepatitis
B and C virus infections. Moreover, precancerous le-
sions of HCC, such as dysplastic foci (DF), including
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creativecommons.org/publicdomain/zero/1.0/dysplastic nodules (DN), including low grade DN (LGDN)
and high grade DN (HGDN), and nodules of altered hepa-
tocytes (NAHs) described previously by Su et al. [2, 3] are
often found in cirrhotic liver tissue. Therefore, mounting
evidence suggests that SCC represents precursor lesions
that are more advanced than LCC in the course of human
hepatocarcinogenesis [4]. Foci of altered hepatocyte (FAH)
is observed in several animal species in the early stages of
hepatocarcinogenesis caused by chemicals, radiation and
chronic infection with hepadnaviruses. FAH is usually
composed of 10–1000 cells, and located in one or more of
the hepatic lobules. It is usually more than 1 mm2 in
cross-sectional area and compresses the surrounding par-
enchyma. Similar lesions have been observed fortuitouslyle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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ceptives and in other pathologic conditions [5–8], particu-
larly in genetic haemochromatosis. It is classified as NAH
if the whole or most of a regenerative nodule is occupied
with a growth predominated FAH [3]. Our previous stud-
ies have demonstrated that part of NAH without SCC and
all NAH with SCC in liver cirrhosis tissue may represent
monoclonal hyperplasia. The occurrence of SCC is a late
event during NAH progression, and a premalignant mor-
phologic phenotype [9]. These observations further sup-
port the contention that NAH is a precancerous lesion of
HCC. However, many professional scholars considered
that the histopathological characteristics of NAH was simi-
lar to that of DN when our previous studies were reviewed
by them [10], and it should be classified as DN according
to their comments and WHO criteria. As the scheme of
preneoplastic and neoplastic nodules during hepatocarci-
nogenesis described by Park [11], these lesions develop
gradually into early HCC, which corresponds to in situ or
microinvasive carcinoma, then develop into progressive
HCC through the stage of “nodule-in-nodule”-type HCC.
Moreover, we applied array-CGH to examine the chromo-
somal abnormalities of 12 monoclonal DN. The results
revealed that there were some changes in DNA copy
number in four chromosomal regions in one DN with
SCC. Namely an increase of DNA copy number was fre-
quently detected at 1q25.2-q21.2, 8q and 19q13.43-q13.12,
while a decrease of DNA copy number was often observed
at 4p, 4q and 8p. In addition, some of the chromosomal
aberrations coincided with those found in HCC. However,
there were no chromosomal abnormalities in another 11
DN without SCC [9]. Thus we believe that surveillance of
the at-risk cirrhotic population could aid earlier detection
of the disease and decrease the cancer-related mortality
rate, but we are limited by the lack of sensitive biomarkers
and reliable histopathological features of precancerous
lesions.
Recently, with the advances in biotechnology, genome-
wide analysis has provided a great deal of information
for identification of candidate genes that may be involved
in carcinogenesis or cancer progression. Single-nucleotide
polymorphism (SNP) arrays have been used to detect genome-
wide abnormalities, such as copy number changes that in-
clude loss of heterozygosity (LOH), deletions, and gene
amplification events in various types of cancer, and
localization of the regions of many oncogens and tumor
suppressor genes (TSGs) [12–14]. Notably, the inactiva-
tion of TSGs has been shown to play an important role in
hepatocarcinogenesis [15]. Allelic deletion manifested as
LOH at polymorphic loci is recognized as a hallmark of
TSGs, whose other allele is inactivated by point mutations,
methylation or by some other mechanism [16]. The delin-
eation of such genetic alterations that occur in precan-
cerous lesions and/or early HCC may be important formonitoring and preventing the occurrence of HCC. Thus, we
investigated molecular karyotypes of 10 matched HCC using
oligonucleotide genotyping Affymetrix single-nucleotide poly-
morphism (SNP) 6.0 arrays, and selected the gene with
high incidence of LOH to validate further by a great deal




Liver tissue samples from 128 cases of surgically resected
HCC (male, n = 108; females, n = 20; average age = 52
years), including 39 cases of HCC without liver cirrhosis
and 89 cases of HCC with liver cirrhosis, were collected
between January 2007 and December 2011 from Tangdu
Hospital, the Fourth Military Medical University (Xi’an,
China). The study protocol was approved by the Medical
Ethics Commission of the Fourth Military Medical University
in Xi’an, China. Written informed consent from all partici-
pants involved in our study was obtained. All the samples
resected surgically were divided into two parts, and one
part was immediately stored at −80 °C, and the other was
fixed in 10 % neutral formalin and embedded in paraffin.
Then, serial sections were stained with haematoxylin and
eosin (H/E). Each case was examined by three pathologists
and diagnosed according to the morphological criteria
of liver cirrhosis and HCC. HCC samples were graded
according to Edmondson’s criteria. 43 DN were selected
from their adjacent HCC according to the criteria de-
scribed by WHO. Every HCC matched its corresponding
DN. None of the patients had received any other ther-
apies such as chemoembolization or chemotherapy before
surgery.
Laser microdissection and DNA extraction
All the samples stored at −80 °C were firstly made into
frozen section, and HCC and liver cirrhosis tissues with
typical histopathological characteristics were observed
and selected, respectively. Then eight serial 10-μm tissue
sections were prepared and placed on UV-absorbing
membrane for laser microdissection by LMD6000 (Leica
Microsystems Ltd, Wetzlar, Germany). After HE-staining,
the slides were mounted on microstat, and the selected
HCC lesion and their adjacent DN were dissected by a
UV laser in mode of motorized optical beam scanning, re-
spectively. The dissectate (with the attached specimen)
dropped by its gravity into the cap of a 0.5-mL microcen-
trifuge tube that was filled with 40 μL lysate buffer and
10 μL protease K. Along with each dissected HCC and
DN, surrounding normal liver tissue of the same size was
isolated and analyzed as a control. The microcentrifuge
tubes were placed in a waterbath (48 °C) to digest the tis-
sue specimens, and then extract DNA using QiaGen kit
(Germany). Finally, genomic DNA was confirmed by gel
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Affymetrix SNP6.0 arrays analysis
The Genome-Wide Human SNP Array 6.0 contains more
than 906,600 single nucleotide polymorphisms (SNPs) and
more than 946,000 probes for the detection of copy num-
ber variation. Each array interrogates SNPs residing on
Nsp I or Sty I PCR amplicons that range in size from
200 to 1000 bp. Genomic DNA of 10 fresh matched
HCC was send to Shanghai Jingtai Gene Tech Biotechnology
Company Limited for SNP6.0 arrays analysis, and per-
formed according to the manufacturer’s commercial proto-
col (Affymetrix; http://www.affymetrix.com). For PCR,
5 μL of diluted, adapter-ligated DNA and 3.5 μM primerFig. 1 Affymetrix SNP6.0 arrays showed that more than 70 % (7/10) cases h
16q11.2- 24.3, respectively. Red color indicated amplification of chromosomwere used in a total volume of 100 μL, and three reactions
were prepared for each DNA sample per enzyme. Sixty
micrograms of purified product were fragmented and end-
labeled using 0.57 mM DLR (GeneChip DNA Labeling
Reagent) and 105U of TdT (Promega) for 2 h at 37 °C.
Hybridization onto the 250 K Nsp and 250 K Sty EA ar-
rays and subsequent washing steps were done exactly as
described by the manufacturer (Affymetrix).
LOH analysis
128 cases of HCC and 43 DN were analyzed for LOH,
along with the surrounding normal liver tissues, by PCR
amplification of polymorphic microsatellite markers. 28
microsatellite markers located in 4q, 8p and 16q were
selected from the Genome Database (Additional file 1).ad chromosomal deletion on 8p23.2-21.2, 4q13.3-35.1, 17p13.3-12, and
al fragment; Blue color indicated neutral LOH without CNV
Table 1 The relationship between the LOH frequency at D8S262
and clinical features of patients with hepatocellular carcinoma
Wk13374861variables Informative cases (n) LOH (%) χ2 P
Age (years)
≤ 52 (n = 68) 49 72.06 2.664 0.103
> 52 (n = 60) 44 73.33
Sex
Male (n = 108) 79 73.15 0.084 0.772
Female (n = 20) 14 70
AFP
≥ 20 ng/mL (n = 76) 58 76.32 1.261 0.261
< 20 ng/mL (n = 52) 35 67.31
HBsAg or HCV
+ (n = 86) 62 72.09 0.042 0.838
- (n = 42) 31 73.81
HCC differentiation
Grade I (n = 14) 9 64.29 0.600 0.741
Grade II (n = 78) 57 73.08
Grade III (n = 36) 27 75
Tumor size
≥ 5 cm (n = 68) 49 72.06 0.026 0.872
< 5 cm (n = 60) 44 73.33
Extrahepatic metastasis
Presence (n = 42) 31 73.81 0.978 0.323
Absence (n = 86) 62 72.09
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μL DNA sample, 4 μL of 10 mM dNTP (Gibco BRL, Life
Technologies, Inc., Gaithersburg, MD, USA), primers A
and B (20 μM each), and 5 μL of 10× buffer, and 2.5U
of Taq DNA polymerase (Gibco BRL). The amplifica-
tion was conducted using a PT-200 thermocycler (MJ
Research, Inc., Watertown, MA, USA) for 35 or 25 cycles
(95 °C for 40 s, 60 °C for 50 s, and 72 °C for 1 min).
Images of PCR gels were recorded and the intensities
of the PCR bands for both alleles were quantified using an
image-analyzing system (LabWorks 3.0, UVP, Cambridge,
UK). A reduction in fluorescence intensity of 50 % or
greater in 1 or more alleles in the HCC and DN (T) com-
pared with the identical allele in the normal liver tissues
(N), was defined as an indicator of a LOH.
Immunohistochemistry
Sections (4-μm) from one representative block for HCC,
DN and the corresponding normal tissue from each case
were deparaffinized, rehydrated in graded alcohols, incu-
bated with H2O2 to block the activity of endogenous
peroxidase, and then subjected to heat-induced epitope
retrieval in 0.1 mol/L citrate buffer at PH 6.0 in a micro-
wave for 20 min. The slides were finally incubated with
a primary monoclonal antibody specific for CUB and
SUSHI multiple domains-1 (CSMD1) (dilution, 1:200,
Boaosen Ltd Company, Beijing, China) for 2 h at room
temperature. After incubation with rabbit anti-mouse sec-
ondary antibody, a subsequent reaction was performed with
biotin-free horse-radish peroxidase enzyme-labeled poly-
mer and visualized using the EnVision plus detection sys-
tem. The chromogen 3,3′-diaminobenzidine (Dako) was
used and sections were counterstained with hematoxylin.
Placental tissues were used as positive controls. Nonspe-
cific IgG was used as a negative control. The CSMD1
staining was considered positive when the granular brown
reaction was seen in the cytoplasm.
Cell lines and culture
The human hepatoma cell lines, HepG2 and SK-hep-1,
were obtained from Cell Resource Center of Chineses
Academy of Medical Sciences and MHCC-97H was pro-
vided by Dr. Dang Zheng, the fourth military medical univer-
sity. The normal human liver cell, HL-7702 was purchased
from JENNIO Biological Technology (Guangzhou, China).
Cell lines were grown in Dulbecco’s modified Eagle’s
medium (Gibco, California, America) supplemented with
10 % fetal bovine serum (Gibco, California, America),100
IU/ml penicillin, and 100 μg/ml streptomycin, at 37 °C in
5 % CO2 atmosphere.
Quantitative RT-PCR
Total RNA was isolated from HL-7702, HepG2, SK-hep-1
and MHCC-97H cells using the RNA sample Total RNAKit (TIANGEN, Beijing, China). Aliquots of 1 ug total RNA
were reverse transcribed into cDNA using the miScript II
RT Kit (QiaGen, Hilden, Germany). Quantitative PCR was
run on an ABI 7500 fast Real-Time PCR system using
miScript SYBR Green PCR Kit (QiaGen, Hilden, Germany).
The reaction cycling conditions were 95 °C for 15 min; 40
cycles at 94 °C for 15 s, 60 °C for 30 s, and 70 °C for 35 s.
The CSMD1 Primers used were: 5′-TCCAGTCATTACC
ACGGCAC-3′ (forward) and 5′-CATGCCCAGCATAGCC
ATTC-3′ (reverse). The GAPDH primers, an internal
normalization control, used were: 5′-GCACCGTCAAGG
CTGAGAAC-3′ (forward) and 5′-TGGTGAAGACGCCA
GTGGA-3′ (reverse). PCR products were analyzed by
electrophoresis on a 8 % acrylamide gel and photographed
using Garestream Health GL-2200 PRO.
Statistical analysis
Statistical analysis was performed using the 2-tailed Fisher
exact test or the χ2 test with the Yates continuity correction.
A P value of <0.05 was considered statistically significant.
Results
The homozygous deletion using SNP6.0 arrays analysis
Affytremix SNP6.0 arrays were applied to 10 matched
HCC and the surrounding non-cancerous liver tissues.
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number variation (CNV) in every chromosome. The red
color indicated chromosomal amplication, and the blue
color represented copy-neutral LOH without CNV. Thus,
we found more than 70 % (7/10) cases had chromosomal
deletion on 8p23.2-21.2, 4q13.3-35.1, 17p13.3-12, and
16q11.2- 24.3, respectively (Fig. 1). The genes located in
these chromosomal fragments included CSMD1, CDH13,
NRG1, PCM1, DLC-1, CMIP, and WWOX et al. Be-
cause previous studies of LOH have reported that al-
lelic loss of 4q, 8p and 16q are the most frequent
chromosomal alteration in a variety of human cancers,
including HCC. Thus, we firstly selected the above genes
located in the short arm of chromosome 4 and 16, and the
long arm of chromosome 8 to investigate further their
LOH in turn by a great deal of samples by a PCR-based
analysis.
LOH for HCC
To date, we examined chromosomal LOH frequency of
128 HCCs at 28 microsatellite markers located in some
gene spanning chromosomal band 4q, 8p and 16q. TheFig. 2 Representative images of PCR gels from a part of microsatellite loci
showed a reduction in fluorescence intensity of 50% or greater in 1 or mo
f, D8S261. N normal liver tissue; HCC hepatocellular carcinomaresults showed that LOH frequency (72.7 %, 93/128) at
D8S262 for 128 cases of HCC was the highest (Table 1),
and the frequency was close to that of SNP6.0 assay. On
polyacrylamide gel electrophoresis, there was a reduc-
tion in fluorescence intensity of 50 % or greater in 1 or
more alleles in the HCC compared with the identical al-
lele in the normal liver tissues (Fig. 2). Moreover, LOH
frequency at D8S262 was not associated with sex, age,
HCC differentiation, number of HCC, serum HBsAg posi-
tivity, or tumor size (Table 2).LOH for DN
Simultaneously, we analyzed chromosomal LOH fre-
quency of 43 DN at the above 28 microsatellite markers.
The result showed that the frequency of chromosomal
LOH were the highest (51.2 %) at D8S262. Namely, there
was also a reduction in fluorescence intensity of 50 % or
greater in 1 or more alleles in the DN compared with the
identical allele in the normal liver tissues (Fig. 3). These
data indicated that chromosomal LOH had occurred in
precancerous lesions of HCC.for HCC. Compared with the surrounding normal liver tissues, HCC
re alleles. a, D4S415; b, D4S2954; c, D8S262; d, D4S3331; e, D8S1725;
Table 2 Relationship between CSMD1 expression and clinical features of patients with hepatocellular carcinoma
Wk13374861variables CSMD1-positive CSMD1-negative χ2 P
Age (years)
≤ 52 (n = 68) 19 49 0.026 0.872
> 52 (n = 60) 16 44
Sex
Male (n = 108) 29 79 0.084 0.772
Female (n = 20) 6 14
AFP
≥ 20 ng/mL (n = 76) 21 55 0.008 0.930
< 20 ng/mL (n = 52) 14 38
HBsAg or HCV
+ (n = 86) 24 62 0.042 0.838
- (n = 42) 11 31
HCC differentiation
Grade I (n = 14) 6 8 2.856 0.240
Grade II (n = 78) 22 56
Grade III (n = 36) 7 29
Tumor size
≥ 5 cm (n = 68) 20 48 0.312 0.576
< 5 cm (n = 60) 15 45
Extrahepatic metastasis
Presence (n = 42) 11 31 0.042 0.838
Absence (n = 86) 24 62
Fig. 3 Representative images of PCR gels from a part of microsatellite loci for NAH. Compared with the surrounding normal liver tissues, NAH showed
a reduction in fluorescence intensity of 50 % or greater in 1 or more alleles. N normal liver tissue; T NAH. Among them, T1 had not occurred LOH
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LOH at D8S262
In the same patient, we found that LOH in HCC was in ac-
cordance with its adjacent DN. In other words, LOH was
detected in HCC if it was found in its adjacent DN. On the
contrary, LOH was not detected in the DN adjacent to
HCC if it was found in HCC. Thus, we concluded that
D8S262 played an important role in hepatocarcinogenesis.
CSMD1 expression in normal hepatic tissues, DN and HCC
The staining pattern of CSMD1 was mainly cytoplasmic
in 128 cases of HCC and the surrounding normal tissues
(Fig. 4), and the positive rate was 27.3 % (35/128) and
82 % (105/128), respectively. The difference reached a
statistic significance (P < 0.05). The above results demon-
strated that CSMD1 might be a TSG for HCC. Moreover,
we found the level of CSMD1 expression was higher in
the well-differentiated HCC than that in the moderate and
poor differentiated HCC (Fig. 5). However, it was not
significant in statistics (P = 0.240). In 43 DN, 33 (33/44,
75 %) were positive for CSMD1. The positive rate was
higher than that (27.3 %) in HCC, but lower than that
(82 %) in the surrounding normal tissues.
CSMD1 expression in HCC cell lines
The results of RT-PCR showed that the expression levels of
CSMD1 mRNA were down-regulated in HepG2, SK-hep-1Fig. 4 The expression of CSMD1 in HCC, NAH, and the surrounding norma
b, positive expression in HCC (100×); c, negative expression in HCC (100×);and MHCC-97H compared with that in HL-7702 (Fig. 6),
indicated that CSMD1 played a role of tumor suppression
gene.
Discussion
Similar to other cancers, the carcinogenesis of hepato-
cellular carcinoma (HCC) is a multi-factor, multi-step,
multi-genes and complicated process resulting from the
accumulation of sequential genetic and epigenetic alter-
ations. Epidemicly, the main causes of HCC are hepatitis
B and C virus infection, dietary exposure to aflatoxin B1
and high-level alcohol consumption. Prolonged exposure
to these risk factors is thought to cause an accumulation
of chromosomal aberrations and altered gene expression,
and eventually results in hepatocarcinogenesis [17–19].
In China, more than 80 % of HCCs develop in patients
with chronic infections with HBV. Histopathologically,
precancerous lesions of HCC, such as DF, including
SCC, DN, and NAH described by Su et al. [3] are often
found in cirrhotic liver tissue, and develop into early
HCC, which corresponds to in situ or microinvasive car-
cinoma, then develop into progressive HCC through the
stage of “nodule-in-nodule”-type HCC. Geneticly, it is
considered that LOH regions found in a significant portion
of tumors are thought to embody tumor suppressor genes
(TSGs). The delineation of such genetic alterations that
occur in precancerous lesions and/or early hepatocellularl liver tissues. a, strong positive expression in normal liver tissue (200×);
d, positive expression in NAH (100×)
Fig. 5 The expression of CSMD1 was stronger in the well-differentiated HCC (a, 200×) than that in the moderate (b, 200×) and poor differentiated
HCC (c, 200×)
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preventing the occurrence of HCC. However, only few of
LOH assays have been reported about precancerous lesions
and early HCC [15, 16, 20]. Our previous studies demon-
strated that part of DN without SCC and all the DN with
SCC in liver cirrhosis tissue were monoclonal hyperplasia,
and neoplastic lesion. Moreover, we revealed that there
were some changes in DNA copy number in four chromo-
somal regions in one DN with SCC applying array-CGH
[9]. These above results showed that some genetic alter-
ation have occurred in some precancerous lesions of HCC.
Some studies have reported that allelic loss of 4q, 8p
and 16q are the most frequent chromosomal alteration
in various human cancers. In particular, the loss of
8p23.1-22 is an important event in the initiation or pro-
motion of HCC [21, 22]. We found that there was high
frequent loss of chromosomal 4q, 8p and 16q according
to the result of Affymetrix SNP6.0 assay. Thus, we se-
lected 28 microsatellite markers at some genes spanning
chromosomal band 4q, 8p and 16q to further elucidate
the precise location of putative TSGs that might poten-
tially be involved in the tumorigenesis of HCC. The results
showed that LOH frequencies at D8S262 for HCC were
found to be 72.7 %, which indicated the gene neighbor-
ing to D8S262 might be a putative TSG related to theFig. 6 The results of RT-PCR showed that the expression levels of CSMD1 m
compared with that in HL-7702hepatocarcinogenesis. Moreover, many evidences have
confirmed this point in many cancers at various levels,
including DNA and RNA level [23]. In addition, some
studies have demonstrated that LOH is detected on
chromosome 8p21.3-p22 in DNs and HCC, and the fre-
quency of LOH is 40.9 % and 42.1 %, respectively [19].
These results suggested that at least one putative tumor
suppressor gene involved in the development of HCC
might be located on 8p21.3-p22. Therefore, this gene
might be related to an early genetic event of hepatocarci-
nogenesis [20]. We examined LOH frequency at D8S262
for DN in order to investigate further the relationship be-
tween DN and HCC. The results demonstrated that LOH
frequency at this locus for DN was 51.2 %, which was
higher than 40.9 %. This indicated that the event of LOH
had occurred in precancerous lesions of HCC, and the
gene neighboring to D8S262 might involved in the occur-
rence and progression of HCC. Simultaneously, it con-
firmed that DN was a hepatic precancerous lesion,
which was coincided in our previous conclusions [9]. The
high incidence of LOH observed at an early stage of tumor
development was speculated that candidate TSGs located
in this region may play an important role in early HCC.
CSMD1 located at the neighbor of D8S262. It encodes
multiple mRNA transcripts with the largest being 14.3 KbRNA were down-regulated in HepG2, SK-hep-1 and MHCC-97H
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contains 71 exons, which encode a 3565 amino acid pro-
tein consisting of 14 CUB domains and 28 SUSHI do-
mains. It is a candidate tumor suppressor gene that maps
to chromosome 8p23, a region deleted in many tumor
types, and has homologies to proteins implicated in car-
cinogenesis. Moreover, many studies have indicated
CSMD1 could be a tumor suppressor gene [23–29]. Thus,
according to the above results, we concluded that CSMD1
might be a TSG, and observed the expression of CSMD1
in HCC, DN and the surrounding liver tissues by immu-
nohistochemical staining methods. The results showed
that the positive rate of CSMD1 increased in turns in
them. This indicated that CSMD1 might be a TSG related
to the occurrence of early HCC. In addition, RT-PCR re-
sults demonstrated that the expression levels of CSMD1
were down-regulated in HCC cell lines compared with
human normal hypertocyte cells HL-7702. Of course,
it will need to be confirmed by a great deal of studies.
Interestingly, Mohamed et al. [23] studied the expression
pattern of the CSMD1 protein in invasive ductal carcin-
oma (IDC), and found that reduction of CSMD1 ex-
pression was significantly associated with high tumor
grade. Their results supported the idea that CSMD1 was a
tumor suppressor gene. Midorikawa et al. [28] found that
homozygous deletions frequently on 8p23.2, and mRNA
expression of the extremely large gene CSMD1 within this
region was decreased in overt HCC, suggesting that
CSMD1 plays a pivotal role in liver cancer progression.
Our results showed that the expression of CSMD1 in the
surrounding normal liver tissues was obviously higher than
that in HCC, and reached a statistic significance. Moreover,
the level of CSMD1 expression was higher in the well-
differentiated HCC than that in the moderate and poor
differentiated HCC though there was not a significant dif-
ference. Thus, we concluded that CSMD1 might a TSG ac-
cording to our results. Lu et al. [21, 22] also found that the
LOH at 8p23.2-21 was significantly more frequent in the
metastatic than corresponding primary tumor lesions in
individual HCC cases, and the significant difference be-
tween them suggests that deletion of 8p23.2-22 may be not
only an early event in the initiation of HCC but also in-
volved in subsequent tumor aggressiveness, especially in
the metastatic progression of HCC. Moreover, they consid-
ered that some unknown genes located adjacent to the
markers D8S262, D8S1819 to D8S1109 and D8S261 play
an important role in HCC. According to the above results,
we found the conclusions were different for the role of
CSMD1 in HCC. This may be related to the difference of
people population. However, we also concluded at least
one critical TSG lie at the restricted minimal regions at
8p23.2-22, and notably, CSMD1 may be one of them. At
present, we considered it was a TSG related to early HCC.
Of course, we need identify the gene by more studies.Conclusions
Our results demonstrated that there were similar genetic
changes between DN and HCC. Moreover, LOH frequen-
cies at D8S262 for DN and HCC were the highest, and the
expression of CSMD1 was obviously lower in HCC than
that in the surrounding liver tissue. Thus, we considered
that CSMD1 may be a critical TSG associated with an
early genetic event of hepatocarcinogenesis, and a pre-
dictor for the monitor and prevention of HCC. Of course,
more studies need to be performed.
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